---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-002577"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2022-01-27T23:59:59+00:00"
generated_at: "2026-06-27T15:03:07.980248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galecto reports safety and efficacy of GB0139 in COVID-19; 21% mortality reduction in high-risk subgroup

## Summary
- Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.
- Target engagement confirmed: statistically significant reduction in serum galectin-3 (p<0.01).
- GB0139-treated patients had significantly greater rate of decline in oxygen requirement vs standard of care.
- In high-risk subgroup, 21% mortality reduction observed; company plans co-development for COVID-19.
- GALACTIC-1 IPF trial: amendment to reduce target patients, topline expected mid-2023.

## SEC filing metadata
- accession: 0001564590-22-002577
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2022-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000156459022002577/0001564590-22-002577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000156459022002577/glto-8k_20220127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-002577
- JSON: https://secwatch.observer/filing/0001564590-22-002577.json
- Plain text: https://secwatch.observer/filing/0001564590-22-002577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.